These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22512725)

  • 1. Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation.
    Mohammad M; Al-Masri IM; Issa A; Al-Ghussein MA; Fararjeh M; Alkhatib H; Taha MO; Bustanji Y
    J Enzyme Inhib Med Chem; 2013 Aug; 28(4):690-4. PubMed ID: 22512725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
    Mohammad MK; Al-Masri IM; Taha MO; Al-Ghussein MA; Alkhatib HS; Najjar S; Bustanji Y
    Eur J Pharmacol; 2008 Apr; 584(1):185-91. PubMed ID: 18295757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation.
    Bustanji Y; Taha MO; Almasri IM; Al-Ghussein MA; Mohammad MK; Alkhatib HS
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):771-8. PubMed ID: 18720192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation.
    Motawi TM; Bustanji Y; El-Maraghy SA; Taha MO; Al Ghussein MA
    J Biochem Mol Toxicol; 2013 Sep; 27(9):425-36. PubMed ID: 23784744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
    Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.
    Bidon-Chanal A; Fuertes A; Alonso D; Pérez DI; Martínez A; Luque FJ; Medina M
    Eur J Med Chem; 2013 Feb; 60():479-89. PubMed ID: 23354070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
    Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.
    La Pietra V; La Regina G; Coluccia A; Famiglini V; Pelliccia S; Plotkin B; Eldar-Finkelman H; Brancale A; Ballatore C; Crowe A; Brunden KR; Marinelli L; Novellino E; Silvestri R
    J Med Chem; 2013 Dec; 56(24):10066-78. PubMed ID: 24295046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors.
    Fukunaga K; Uehara F; Aritomo K; Shoda A; Hiki S; Okuyama M; Usui Y; Watanabe K; Yamakoshi K; Kohara T; Hanano T; Tanaka H; Tsuchiya S; Sunada S; Saito K; Eguchi J; Yuki S; Asano S; Tanaka S; Mori A; Yamagami K; Baba H; Horikawa T; Fujimura M
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6933-7. PubMed ID: 24176395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.
    Miyazaki Y; Maeda Y; Sato H; Nakano M; Mellor GW
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1967-71. PubMed ID: 18280153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS; Balaji B; Rani P; Ramanathan M
    J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
    Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
    Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3β inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues.
    Han S; Zhou W; Zhuang C; Chen F
    Bioorg Chem; 2022 Feb; 119():105537. PubMed ID: 34902644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
    Kohara T; Nakayama K; Watanabe K; Kusaka SI; Sakai D; Tanaka H; Fukunaga K; Sunada S; Nabeno M; Saito KI; Eguchi JI; Mori A; Tanaka S; Bessho T; Takiguchi-Hayashi K; Horikawa T
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3733-3738. PubMed ID: 28712706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.
    Song EY; Palladinetti P; Klamer G; Ko KH; Lindeman R; O'Brien TA; Dolnikov A
    Exp Hematol; 2010 Oct; 38(10):908-921.e1. PubMed ID: 20540984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.
    Chun K; Park JS; Lee HC; Kim YH; Ye IH; Kim KJ; Ku IW; Noh MY; Cho GW; Kim H; Kim SH; Kim J
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3983-7. PubMed ID: 23683591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors.
    Luo G; Chen L; Burton CR; Xiao H; Sivaprakasam P; Krause CM; Cao Y; Liu N; Lippy J; Clarke WJ; Snow K; Raybon J; Arora V; Pokross M; Kish K; Lewis HA; Langley DR; Macor JE; Dubowchik GM
    J Med Chem; 2016 Feb; 59(3):1041-51. PubMed ID: 26751161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
    Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC
    Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent and bioavailable GSK-3beta inhibitors.
    Gong L; Hirschfeld D; Tan YC; Heather Hogg J; Peltz G; Avnur Z; Dunten P
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1693-6. PubMed ID: 20138512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.